Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

200.74 +0.33 (+0.16%)
Streaming Delayed Price Updated: 10:58 AM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
33 Stocks Moving In Friday's Mid-Day Session
Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy. 
Via Benzinga
Embattled Biotech Seagen Rockets On Rumors Merck Could Buy It
The rumor emerges shortly after the company's former CEO was arrested. 
Via Investor's Business Daily
Merck Shows Takeover Interest In Seagen: WSJ
 
Via Benzinga
Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence
 
Via Benzinga
Seagen CEO Clay Siegall Placed On Leave After Domestic Violence Claim
Siegall says he is going through a divorce and denied the claim. 
Via Investor's Business Daily
Expert Ratings for Seagen
Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings: 
Via Benzinga
$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today
Seagen (NASDAQ:SGEN) has outperformed the market over the past 20 years by 12.54% on an annualized basis producing an average annual return of 19.38%. Currently, Seagen has a market capitalization of... 
Via Benzinga
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications
 
Via Benzinga
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Seagen Inc.
Via Business Wire
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Genmab A/S
Via Business Wire
10 Biggest Price Target Changes For Monday
Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday. 
Via Benzinga
ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
5 Growth Stocks to Buy Now
EPS estimates are generally a strong indication of future growth. That's just one part of finding reliable growth stocks. 
Via InvestorPlace
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
From Takeda Pharmaceutical Company Limited
Via Business Wire
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
 
Via Benzinga
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Seagen CEO Clay Siegall Resigns After Domestic Violence Arrest
Clay Siegall and the board agreed it would be in investors' best interest if he resigned. 
Via Investor's Business Daily
Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
From Seagen Inc.
Via Business Wire
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
From Seagen Inc.
Via Business Wire
103 Biggest Movers From Yesterday
Gainers 
Via Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Looking Into Seattle Genetics's Return On Capital Employed
According to Benzinga Pro data, during Q1, Seattle Genetics (NASDAQ:SGEN) posted sales of $426.46 million. Earnings were up 21.84%, but Seattle Genetics still reported an overall loss of $136.49... 
Via Benzinga
4 Healthcare Funds With "Double Discounts"
There's nothing that closed-end fund investors love more than finding a smartly run fund in an unfairly beaten-down sector. This hands us a nice discount plus a much bigger dividend. Let's take a look... 
Via Talk Markets
Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales
Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance. 
Via Benzinga
Recap: Seagen Q1 Earnings
Seagen (NASDAQ:SGEN) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Seagen beat estimated earnings by... 
Via Benzinga
Seagen Reports First Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seagen Inc.
Via Business Wire
Earnings Scheduled For April 28, 2022
Companies Reporting Before The Bell • PBF Energy (NYSE:PBF) is projected to report quarterly earnings at $0.26 per share on revenue of $8.24 billion. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.